Clinical trials: T-Cell Chronic Lymphocytic Leukemia
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
B Cell Lymphoma, B Cell Leukemia
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
- Trial name
- NCT04156243
- Testing
- CD19 CARvac T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Leukemia, B-cell, Lymphoma, B-Cell
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04649983
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL)
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin…
- Conditions
- Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL)
- Trial name
- NCT01994382
- Testing
- Cerdulatinib, Rituximab
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Non Hodgkin Lymphoma, Multiple Myeloma
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial.
- Conditions
- Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03436771
- Testing
- JCAR017, JCARH125
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Graft Versus Host Disease, Leukemia
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
RATIONALE: OTI-010 may be effective for graft-versus-host disease prophylaxis (prevention) in patients who are undergoing donor peripheral stem cell transplantation for hematologic malignancies (cancer of the blood or bone…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00081055
- Testing
- autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Leukemia, B-cell, Lymphoma, B-Cell
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04648475
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma
Study of MLN8237 in Participants With Advanced Hematological Malignancies
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma
- Trial name
- NCT00697346
- Testing
- Alisertib
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma
Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
- Trial name
- NCT05544019
- Testing
- SGR-1505
- Where
- 36 sites in United States, France and 6 more
- Volunteers
- 98 people
- Sponsor
- Schrödinger, Inc.
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT01767766
- Testing
- TGR-1202
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia, B-Cell
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
In the conventional treatment options, B cell leukemia could be treated with chemotherapy drugs or HSCT. But chemotherapy could barely cured leukemia.
- Trial name
- NCT02672501
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
- Trial name
- NCT06547528
- Testing
- ONO-4685
- Where
- 14 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Lymphoma, B-Cell, Leukemia, B-cell
CAR-T Cells in the Treatment of Malignant Hematological Tumors
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
- Conditions
- Lymphoma, B-Cell, Leukemia, B-cell, Leukemia, T-Cell, Multiple Myeloma
- Trial name
- NCT05619861
- Testing
- CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, Lymphoma, Large B-Cell, Diffuse
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.
- Conditions
- Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell
- Trial name
- NCT04271410
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Phase 1b Safety and Efficacy Study of TRU-016
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in…
- Trial name
- NCT01644253
- Testing
- 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- Aptevo Therapeutics